Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab

黄斑变性 医学 眼科 验光服务
作者
Sing Yue Sim,Evangelia Chalkiadaki,Georgios Koutsocheras,Luke Nicholson,Sobha Sivaprasad,Praveen J. Patel,Senthil Selvam,Bishwanath Pal,Pearse A. Keane,B. Bhatia,Robin Hamilton
出处
期刊:Ophthalmology Retina [Elsevier]
标识
DOI:10.1016/j.oret.2024.07.020
摘要

To report 1-year anatomic and functional real-world outcomes of patients with treatment-intensive neovascular age-related macular degeneration (nAMD) switched to faricimab. Retrospective multicenter cohort study. Consecutive nAMD patients on 4-weekly treatment interval with either ranibizumab or aflibercept 2 mg in the last 3 visits within a treat-and-extend protocol (high treatment burden) before switch to faricimab at Moorfields Eye Hospital between September 5, 2022 and December 5, 2022. Patients with nAMD switched to faricimab were identified from electronic medical records and those who met criteria of high treatment burden were included. Data collected included preswitch and postswitch visual acuity (VA), treatment intervals, baseline macular morphology, central subfield thickness (CST), macular fluid status, and adverse events. Visual acuity, CST, presence of intraretinal fluid, subretinal fluid, and injection intervals over 1 year after switch to faricimab. A total of 130 of 286 (45.5%) eyes met inclusion criteria of being switched due to high treatment burden and 117 were included in analysis. Before switch, these eyes received mean total number of injections of 33.4 ± 19.6 over a mean of 51.3 ± 34.9 months. Mean number of injections in 12 months preceding switch was 10.1 ± 1.6 and mean interval of the preceding 3 injections was 4.2 ± 0.3 weeks. Mean VA, CST, and percentage of patients with dry macula before switch were 66.0 ± 11.9 ETDRS letters, 259.6 ± 76.0 μm and 18.3% respectively. After switch, there was no statistical difference in mean VA throughout follow-up period. Mean CST statistically significantly reduced after the third faricimab injection and at 12 months by 20.0 μm (P = 0.035) and 22.1 μm (P = 0.041) respectively. Mean treatment intervals increased to 6.9 ± 2.3 weeks (P < 0.005) at 12 months with 42.9% and 11.4% of patients being on ≥8-weekly and ≥12-weekly treatment intervals, respectively. At 12 months, nAMD patients with previous record of high treatment burden when switched to faricimab maintained VAs and improved anatomic outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate these findings. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wfmmm完成签到,获得积分10
刚刚
虚心昊强发布了新的文献求助10
1秒前
柳沙鸣完成签到,获得积分20
1秒前
2秒前
2秒前
2秒前
2秒前
吕航宇发布了新的文献求助10
4秒前
4秒前
cherry发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
Yziii应助闻屿采纳,获得20
5秒前
5秒前
6秒前
ding应助嘻嘻嘻采纳,获得10
6秒前
Jasper应助柳沙鸣采纳,获得10
7秒前
科研通AI2S应助ymym采纳,获得10
7秒前
NexusExplorer应助一一采纳,获得10
8秒前
lyh2234完成签到 ,获得积分10
9秒前
Siri发布了新的文献求助10
9秒前
乐乐应助何aa采纳,获得10
9秒前
虬江学者发布了新的文献求助10
10秒前
10秒前
11秒前
奥利奥配奶完成签到,获得积分10
11秒前
Cytosol发布了新的文献求助10
12秒前
酷波er应助善良青筠采纳,获得10
12秒前
稳重笑南完成签到,获得积分10
12秒前
雨碎寒江发布了新的文献求助10
12秒前
12秒前
12秒前
完美世界应助爬不起来采纳,获得10
13秒前
雪碧呀发布了新的文献求助20
13秒前
13秒前
科研小菜鸡完成签到,获得积分10
14秒前
15秒前
科目三应助jiangmingjiao采纳,获得10
17秒前
所所应助鸿儒采纳,获得10
17秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3076615
求助须知:如何正确求助?哪些是违规求助? 2729637
关于积分的说明 7509187
捐赠科研通 2377811
什么是DOI,文献DOI怎么找? 1260829
科研通“疑难数据库(出版商)”最低求助积分说明 611183
版权声明 597203